

# Myelodysplastic Syndrome-EMEA Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/M9C7D76F5CBMEN.html>

Date: May 2018

Pages: 134

Price: US\$ 3,480.00 (Single User License)

ID: M9C7D76F5CBMEN

## Abstracts

### Report Summary

Myelodysplastic Syndrome-EMEA Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Myelodysplastic Syndrome industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole EMEA and Regional Market Size of Myelodysplastic Syndrome 2013-2017, and development forecast 2018-2023

Main market players of Myelodysplastic Syndrome in EMEA, with company and product introduction, position in the Myelodysplastic Syndrome market

Market status and development trend of Myelodysplastic Syndrome by types and applications

Cost and profit status of Myelodysplastic Syndrome, and marketing status

Market growth drivers and challenges

The report segments the EMEA Myelodysplastic Syndrome market as:

EMEA Myelodysplastic Syndrome Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Europe

Middle East

Africa

EMEA Myelodysplastic Syndrome Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

Alkylating Agents  
Cytotoxic Antibiotics  
Topoisomerase Inhibitors  
Others

EMEA Myelodysplastic Syndrome Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Hospital  
Clinic

EMEA Myelodysplastic Syndrome Market: Players Segment Analysis (Company and  
Product introduction, Myelodysplastic Syndrome Sales Volume, Revenue, Price and  
Gross Margin):

Celgene  
Novartis  
Otsuka  
Actinium Pharmaceuticals  
Accelaron Pharma  
Bellicum Pharmaceuticals  
Cornerstone Pharmaceuticals  
CTI BioPharma  
Onconova Therapeutics  
Strategia Therapeutics  
KaloBios Pharmaceuticals  
Kiadis Pharma  
Mirati Therapeutics  
Astex  
Celator Pharmaceuticals  
Eli-lilly  
Sunesis Pharmaceuticals  
Targazyme  
Gamida Cell  
GlaxoSmithKline  
Sumitomo Dainippon Pharma

## TetraLogic Pharmaceuticals

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF MYELOYDYSPLASTIC SYNDROME**

- 1.1 Definition of Myelodysplastic Syndrome in This Report
- 1.2 Commercial Types of Myelodysplastic Syndrome
  - 1.2.1 Alkylating Agents
  - 1.2.2 Cytotoxic Antibiotics
  - 1.2.3 Topoisomerase Inhibitors
  - 1.2.4 Others
- 1.3 Downstream Application of Myelodysplastic Syndrome
  - 1.3.1 Hospital
  - 1.3.2 Clinic
- 1.4 Development History of Myelodysplastic Syndrome
- 1.5 Market Status and Trend of Myelodysplastic Syndrome 2013-2023
  - 1.5.1 Asia Pacific Myelodysplastic Syndrome Market Status and Trend 2013-2023
  - 1.5.2 Regional Myelodysplastic Syndrome Market Status and Trend 2013-2023

### **CHAPTER 2 ASIA PACIFIC MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Myelodysplastic Syndrome in Asia Pacific 2013-2017
- 2.2 Consumption Market of Myelodysplastic Syndrome in Asia Pacific by Regions
  - 2.2.1 Consumption Volume of Myelodysplastic Syndrome in Asia Pacific by Regions
  - 2.2.2 Revenue of Myelodysplastic Syndrome in Asia Pacific by Regions
- 2.3 Market Analysis of Myelodysplastic Syndrome in Asia Pacific by Regions
  - 2.3.1 Market Analysis of Myelodysplastic Syndrome in China 2013-2017
  - 2.3.2 Market Analysis of Myelodysplastic Syndrome in Japan 2013-2017
  - 2.3.3 Market Analysis of Myelodysplastic Syndrome in Korea 2013-2017
  - 2.3.4 Market Analysis of Myelodysplastic Syndrome in India 2013-2017
  - 2.3.5 Market Analysis of Myelodysplastic Syndrome in Southeast Asia 2013-2017
  - 2.3.6 Market Analysis of Myelodysplastic Syndrome in Australia 2013-2017
- 2.4 Market Development Forecast of Myelodysplastic Syndrome in Asia Pacific 2018-2023
  - 2.4.1 Market Development Forecast of Myelodysplastic Syndrome in Asia Pacific 2018-2023
  - 2.4.2 Market Development Forecast of Myelodysplastic Syndrome by Regions 2018-2023

### **CHAPTER 3 ASIA PACIFIC MARKET STATUS AND FORECAST BY TYPES**

### 3.1 Whole Asia Pacific Market Status by Types

3.1.1 Consumption Volume of Myelodysplastic Syndrome in Asia Pacific by Types

3.1.2 Revenue of Myelodysplastic Syndrome in Asia Pacific by Types

### 3.2 Asia Pacific Market Status by Types in Major Countries

3.2.1 Market Status by Types in China

3.2.2 Market Status by Types in Japan

3.2.3 Market Status by Types in Korea

3.2.4 Market Status by Types in India

3.2.5 Market Status by Types in Southeast Asia

3.2.6 Market Status by Types in Australia

### 3.3 Market Forecast of Myelodysplastic Syndrome in Asia Pacific by Types

## **CHAPTER 4 ASIA PACIFIC MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

### 4.1 Demand Volume of Myelodysplastic Syndrome in Asia Pacific by Downstream Industry

### 4.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Major Countries

4.2.1 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in China

4.2.2 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Japan

4.2.3 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Korea

4.2.4 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in India

### 4.2.5 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Southeast Asia

### 4.2.6 Demand Volume of Myelodysplastic Syndrome by Downstream Industry in Australia

### 4.3 Market Forecast of Myelodysplastic Syndrome in Asia Pacific by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF MYELODYSPLASTIC SYNDROME**

### 5.1 Asia Pacific Economy Situation and Trend Overview

### 5.2 Myelodysplastic Syndrome Downstream Industry Situation and Trend Overview

## **CHAPTER 6 MYELODYSPLASTIC SYNDROME MARKET COMPETITION STATUS BY MAJOR PLAYERS IN ASIA PACIFIC**

- 6.1 Sales Volume of Myelodysplastic Syndrome in Asia Pacific by Major Players
- 6.2 Revenue of Myelodysplastic Syndrome in Asia Pacific by Major Players
- 6.3 Basic Information of Myelodysplastic Syndrome by Major Players
  - 6.3.1 Headquarters Location and Established Time of Myelodysplastic Syndrome Major Players
  - 6.3.2 Employees and Revenue Level of Myelodysplastic Syndrome Major Players
- 6.4 Market Competition News and Trend
  - 6.4.1 Merger, Consolidation or Acquisition News
  - 6.4.2 Investment or Disinvestment News
  - 6.4.3 New Product Development and Launch

## **CHAPTER 7 MYELOYDYSPLASTIC SYNDROME MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

- 7.1 Celgene
  - 7.1.1 Company profile
  - 7.1.2 Representative Myelodysplastic Syndrome Product
  - 7.1.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celgene
- 7.2 Novartis
  - 7.2.1 Company profile
  - 7.2.2 Representative Myelodysplastic Syndrome Product
  - 7.2.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Novartis
- 7.3 Otsuka
  - 7.3.1 Company profile
  - 7.3.2 Representative Myelodysplastic Syndrome Product
  - 7.3.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Otsuka
- 7.4 Actinium Pharmaceuticals
  - 7.4.1 Company profile
  - 7.4.2 Representative Myelodysplastic Syndrome Product
  - 7.4.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Actinium Pharmaceuticals
- 7.5 Acceleron Pharma
  - 7.5.1 Company profile
  - 7.5.2 Representative Myelodysplastic Syndrome Product
  - 7.5.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Acceleron Pharma
- 7.6 Bellicum Pharmaceuticals
  - 7.6.1 Company profile

- 7.6.2 Representative Myelodysplastic Syndrome Product
- 7.6.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Bellicum Pharmaceuticals
- 7.7 Cornerstone Pharmaceuticals
  - 7.7.1 Company profile
  - 7.7.2 Representative Myelodysplastic Syndrome Product
  - 7.7.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Cornerstone Pharmaceuticals
- 7.8 CTI BioPharma
  - 7.8.1 Company profile
  - 7.8.2 Representative Myelodysplastic Syndrome Product
  - 7.8.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of CTI BioPharma
- 7.9 Onconova Therapeutics
  - 7.9.1 Company profile
  - 7.9.2 Representative Myelodysplastic Syndrome Product
  - 7.9.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Onconova Therapeutics
- 7.10 Strategia Therapeutics
  - 7.10.1 Company profile
  - 7.10.2 Representative Myelodysplastic Syndrome Product
  - 7.10.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Strategia Therapeutics
- 7.11 KaloBios Pharmaceuticals
  - 7.11.1 Company profile
  - 7.11.2 Representative Myelodysplastic Syndrome Product
  - 7.11.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of KaloBios Pharmaceuticals
- 7.12 Kiadis Pharma
  - 7.12.1 Company profile
  - 7.12.2 Representative Myelodysplastic Syndrome Product
  - 7.12.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Kiadis Pharma
- 7.13 Mirati Therapeutics
  - 7.13.1 Company profile
  - 7.13.2 Representative Myelodysplastic Syndrome Product
  - 7.13.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Mirati Therapeutics
- 7.14 Astex

- 7.14.1 Company profile
- 7.14.2 Representative Myelodysplastic Syndrome Product
- 7.14.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Astex
- 7.15 Celator Pharmaceuticals
  - 7.15.1 Company profile
  - 7.15.2 Representative Myelodysplastic Syndrome Product
  - 7.15.3 Myelodysplastic Syndrome Sales, Revenue, Price and Gross Margin of Celator Pharmaceuticals
- 7.16 Eli-lilly
- 7.17 Sunesis Pharmaceuticals
- 7.18 Targazyme
- 7.19 Gamida Cell
- 7.20 GlaxoSmithKline
- 7.21 Sumitomo Dainippon Pharma
- 7.22 TetraLogic Pharmaceuticals

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 8.1 Industry Chain of Myelodysplastic Syndrome
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 9.1 Cost Structure Analysis of Myelodysplastic Syndrome
- 9.2 Raw Materials Cost Analysis of Myelodysplastic Syndrome
- 9.3 Labor Cost Analysis of Myelodysplastic Syndrome
- 9.4 Manufacturing Expenses Analysis of Myelodysplastic Syndrome

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF MYELODYSPLASTIC SYNDROME**

- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning



- 10.2.1 Pricing Strategy
- 10.2.2 Brand Strategy
- 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Myelodysplastic Syndrome-EMEA Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/M9C7D76F5CBMEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9C7D76F5CBMEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970